- Published at
- by manilatimes.net
positive
positive
News for Myriad Genetics, Inc. (MYD.DE)
- Published at
- by gurufocus.com
positivepositiveMyriad Genetics Names Brian Donnelly as New Chief Commercial Officer
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. ( MYGN), a leader in molecular diagnostics testing and precision medicine, announced- Published at
- by benzinga.com
mixedmixedExcelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - American Axle & Mfg Hldgs (NYSE:AXL), Alumis (NASDAQ:ALMS)
U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Tuesday. Shares of Excelerate Energy, Inc. EE fell sharply in ...- Published at
- by benzinga.com
mixedmixedWhy PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies (NASDAQ:BIAF), Cambium Networks (NASDAQ:CMBM)
Shares of PVH Corp. PVH rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Calvin Kle...- Published at
- by benzinga.com
mixedmixedWhy PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies (NASDAQ:BIAF), Cambium Networks (NASDAQ:CMBM)
Shares of PVH Corp. PVH rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Calvin Kle...- Published at
- by gurufocus.com
neutralneutralMyriad Genetics (MYGN) Stock Jumps on Analyst Upgrade
Shares of Myriad Genetics (MYGN) surged 3.51% today after analysts at Piper Sandler upgraded the stock's rating from Neutral to Buy. This upgrade reflects optim- Published at
- by benzinga.com
mixedmixedThis HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Crocs (NASDAQ:CROX), Eaton Corp (NYSE:ETN)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...- Published at
- by gurufocus.com
negativenegativeMyriad Genetics Inc (MYGN) Partners with Gabbi to Enhance Breast Cancer Risk Assessment
On February 27, 2025, Myriad Genetics Inc (MYGN), a leader in molecular diagnostics and precision medicine, announced a strategic collaboration with Gabbi, a te- Published at
- by manilatimes.net
mixedmixed- Published at
- by gurufocus.com
positivepositiveMyriad Genetics Inc (MYGN) Reports Strong Q4 2024 Results and Strategic Developments
Myriad Genetics Inc (MYGN), a leader in genetic testing and precision medicine, announced its financial results for the fourth quarter and full-year ending Dece- Published at
- by gurufocus.com
positivepositiveMyriad Genetics Inc (MYGN) Announces Leadership Transition with New CEO and COO Appointments
Myriad Genetics Inc (MYGN), a prominent player in molecular diagnostics and precision medicine, announced on February 24, 2025, the appointment of Sam Raha as t- Published at
- by gurufocus.com
neutralneutralMyriad Genetics Inc (MYGN) Partners with PATHOMIQ for AI-Driven Prostate Cancer Diagnostics
On February 24, 2025, Myriad Genetics Inc (MYGN), a leader in molecular diagnostic testing and precision medicine, announced a strategic collaboration with PATH- Published at
- by gurufocus.com
positivepositiveMyriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Partnerships Propel Future Prospects
Revenue Growth: 11% increase in 2024 compared to 2023.Adjusted Gross Profit: Approximately $589 million in 2024.Adjusted EBITDA: $40 million in 2024.Adjusted E- Published at
- by gurufocus.com
positivepositiveQ4 2024 Myriad Genetics Inc Earnings Call Transcript
Feb 24, 2025 / 09:30PM GMTOperator Good day, and thank you for standing by. Welcome to the Myriad Genetics fourth quarter 2024 financial earnings conference cal- Published at
- by seekingalpha.com
positivepositiveMyriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Results Conference Call February 24, 2025 4:30 PM ETCompany ParticipantsMatt Scalo - Senior Vice President of...- Published at
- by gurufocus.com
neutralneutralMyriad Genetics Reports Q4 Revenue of $211 Million, Slightly Missing Estimates; EPS Aligns with Expectations
Quarterly Revenue: $211 million, slightly below the estimated $211.62 million, but up 7% year-over-year, driven by strong demand in Pharmacogenomics and Prenat- Published at
- by gurufocus.com
positivepositiveMyriad Genetics Announces Senior Leadership Transition
Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025 SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. ( MYGN- Published at
- by gurufocus.com
neutralneutralMyriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
Highlights Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
neutralneutralMyriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
Management will participate in three upcoming investor healthcare conferences SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. ( MYGN